Amgen Inc (AMGN) 122.65 $AMGN
Top 5 Earnings Reports To Watch After The Close Tue.
at Investor's Business Daily - Mon Jul 28, 5:49PM CDT
With earnings season still in full swing, several notable companies are set to report Tuesday after the market closes. U.S. Silica (SLCA) is projected to see a 21% jump in second-quarter profit to 46 cents a share. Revenue is seen climbing 47% to...
Final Glance: Biotechnology companies
AP - Mon Jul 28, 5:05PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Will Amgen (AMGN) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 4:15PM CDT
Amgen Inc. (AMGN) is set to report second quarter 2014 results on Jul 29 after the market closes.
Business events scheduled for Tuesday
By The Associated Press - AP - Mon Jul 28, 1:10PM CDT
Major business and economic events scheduled for Tuesday:
Midday Glance: Biotechnology companies
AP - Mon Jul 28, 12:32PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Pfizer, Merck, Amgen Near Q2 Earnings Reports
at Investor's Business Daily - Mon Jul 28, 12:02PM CDT
Big pharma Pfizer (PFE) got a downgrade ahead of its Q2 earnings report scheduled for Tuesday, a day that will also feature reports from fellow big pharma Merck (MRK) as well as big biotech Amgen (AMGN). Analysts on average expect Pfizer earnings of...
Amgen Shares Have the Right Prescription for Long-Term Growth
at The Street - Mon Jul 28, 11:06AM CDT
On the basis of improving cash flow and positive clinical trial data, these shares should reach $135 in the next six to 12 months.
Early Glance: Biotechnology companies
AP - Mon Jul 28, 9:33AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
Amgen's board to pay Q3 2014 dividend of USD0.61 per share
M2 - Mon Jul 28, 5:10AM CDT
The board of directors of Amgen (NasdaqGS:AMGN), a human therapeutics company, on Friday declared its dividend of USD0.61 per share for the third quarter of 2014.
Cancer Vaccines market set to reach $9 billion by 2022
PRWeb - Sun Jul 27, 6:14AM CDT
With cancer vaccines known to earn higher profits owing to the nature of the disease and the urgency in the demand, SMi's 3rd annual Cancer Vaccines conference comes at the perfect time to explore the latest developments oncolytic vaccines, T cell immune monitoring, cancer immunotherapy, biomarker guided development, plus much more.
Amgen Announces 2014 Third Quarter Dividend
PR Newswire - Fri Jul 25, 3:00PM CDT
Amgen (NASDAQ: AMGN) announced that its Board of Directors today declared a $0.61 per share dividend for the third quarter of 2014. The dividend will be paid on Sept. 5, 2014, to all stockholders of record as of the close of business on Aug. 14, 2014.
Bayer/Amgen's Nexavar Does Not Show Resilience in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 1:45PM CDT
Bayer (BAYRY) and Amgen's (AMGN) Nexavar performed disppointingly in a late stage study.
Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR® (sorafenib) in Patients with Advanced Breast Cancer
PR Newswire - Fri Jul 25, 1:30AM CDT
Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary (NASDAQ: AMGN), today announced that an investigational Phase 3 trial of NEXAVAR® (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).
Top 5 Earnings Reports To Watch After The Close Tue.
at Investor's Business Daily - Mon Jul 28, 5:49PM CDT
With earnings season still in full swing, several notable companies are set to report Tuesday after the market closes. U.S. Silica (SLCA) is projected to see a 21% jump in second-quarter profit to 46 cents a share. Revenue is seen climbing 47% to...
Final Glance: Biotechnology companies
AP - Mon Jul 28, 5:05PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Will Amgen (AMGN) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 4:15PM CDT
Amgen Inc. (AMGN) is set to report second quarter 2014 results on Jul 29 after the market closes.
Business events scheduled for Tuesday
By The Associated Press - AP - Mon Jul 28, 1:10PM CDT
Major business and economic events scheduled for Tuesday:
Midday Glance: Biotechnology companies
AP - Mon Jul 28, 12:32PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Pfizer, Merck, Amgen Near Q2 Earnings Reports
at Investor's Business Daily - Mon Jul 28, 12:02PM CDT
Big pharma Pfizer (PFE) got a downgrade ahead of its Q2 earnings report scheduled for Tuesday, a day that will also feature reports from fellow big pharma Merck (MRK) as well as big biotech Amgen (AMGN). Analysts on average expect Pfizer earnings of...
Amgen Shares Have the Right Prescription for Long-Term Growth
at The Street - Mon Jul 28, 11:06AM CDT
On the basis of improving cash flow and positive clinical trial data, these shares should reach $135 in the next six to 12 months.
Early Glance: Biotechnology companies
AP - Mon Jul 28, 9:33AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
Amgen's board to pay Q3 2014 dividend of USD0.61 per share
M2 - Mon Jul 28, 5:10AM CDT
The board of directors of Amgen (NasdaqGS:AMGN), a human therapeutics company, on Friday declared its dividend of USD0.61 per share for the third quarter of 2014.
Cancer Vaccines market set to reach $9 billion by 2022
PRWeb - Sun Jul 27, 6:14AM CDT
With cancer vaccines known to earn higher profits owing to the nature of the disease and the urgency in the demand, SMi's 3rd annual Cancer Vaccines conference comes at the perfect time to explore the latest developments oncolytic vaccines, T cell immune monitoring, cancer immunotherapy, biomarker guided development, plus much more.
Amgen Announces 2014 Third Quarter Dividend
PR Newswire - Fri Jul 25, 3:00PM CDT
Amgen (NASDAQ: AMGN) announced that its Board of Directors today declared a $0.61 per share dividend for the third quarter of 2014. The dividend will be paid on Sept. 5, 2014, to all stockholders of record as of the close of business on Aug. 14, 2014.
Bayer/Amgen's Nexavar Does Not Show Resilience in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 1:45PM CDT
Bayer (BAYRY) and Amgen's (AMGN) Nexavar performed disppointingly in a late stage study.
Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR® (sorafenib) in Patients with Advanced Breast Cancer
PR Newswire - Fri Jul 25, 1:30AM CDT
Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary (NASDAQ: AMGN), today announced that an investigational Phase 3 trial of NEXAVAR® (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).
